Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
$0.00
$0.00
$0.00
$0.05
N/A-2.8213,198 shs241 shs
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
$3.39
-4.2%
$3.38
$2.55
$6.12
$38.18M1.5479,194 shs737,304 shs
ObsEva SA stock logo
OBSV
ObsEva
$0.00
$0.08
$2.14
$7.94M0.688.94 million shsN/A
Savara Inc. stock logo
SVRA
Savara
$2.37
+4.4%
$2.53
$1.89
$5.11
$392.34M0.311.27 million shs1.47 million shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
0.00%0.00%-95.00%-90.00%-99.50%
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
-4.24%+6.60%+0.59%+11.51%-20.79%
ObsEva SA stock logo
OBSV
ObsEva
0.00%0.00%0.00%0.00%0.00%
Savara Inc. stock logo
SVRA
Savara
+4.41%+12.86%-0.42%-10.23%-51.03%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
2.4939 of 5 stars
3.52.00.00.03.20.80.6
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/AN/AN/AN/AN/A
Savara Inc. stock logo
SVRA
Savara
2.2081 of 5 stars
3.31.00.00.01.43.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
0.00
N/AN/AN/A
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
3.00
Buy$25.00637.46% Upside
ObsEva SA stock logo
OBSV
ObsEva
0.00
N/AN/AN/A
Savara Inc. stock logo
SVRA
Savara
2.60
Moderate Buy$5.60136.29% Upside

Current Analyst Ratings Breakdown

Latest OBSV, CALA, SVRA, and LTRN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/29/2025
Savara Inc. stock logo
SVRA
Savara
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$6.00 ➝ $2.00
5/28/2025
Savara Inc. stock logo
SVRA
Savara
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetIn-Line ➝ In-Line$3.00 ➝ $2.00
5/28/2025
Savara Inc. stock logo
SVRA
Savara
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $8.00
5/28/2025
Savara Inc. stock logo
SVRA
Savara
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$8.00 ➝ $7.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/AN/AN/AN/A
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
N/AN/AN/AN/A$1.96 per shareN/A
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/A$0.41 per shareN/A
Savara Inc. stock logo
SVRA
Savara
N/AN/AN/AN/A$1.00 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
-$39.65MN/A0.00N/AN/AN/AN/AN/A
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
-$20.78M-$1.84N/AN/AN/AN/A-83.26%-70.65%8/6/2025 (Estimated)
ObsEva SA stock logo
OBSV
ObsEva
-$58.38M-$0.92N/AN/AN/AN/A-416.36%-92.01%N/A
Savara Inc. stock logo
SVRA
Savara
-$95.88M-$0.48N/AN/AN/AN/A-65.88%-52.35%8/11/2025 (Estimated)

Latest OBSV, CALA, SVRA, and LTRN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
-$0.49-$0.42+$0.07-$0.42N/AN/A
5/13/2025Q1 2025
Savara Inc. stock logo
SVRA
Savara
-$0.12-$0.12N/A-$0.12N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/AN/AN/A
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
N/AN/AN/AN/AN/A
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/AN/A
Savara Inc. stock logo
SVRA
Savara
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/A
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
N/A
4.86
4.86
ObsEva SA stock logo
OBSV
ObsEva
N/A
0.61
0.61
Savara Inc. stock logo
SVRA
Savara
0.20
14.91
14.91

Institutional Ownership

CompanyInstitutional Ownership
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/A
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
28.62%
ObsEva SA stock logo
OBSV
ObsEva
17.52%
Savara Inc. stock logo
SVRA
Savara
87.93%

Insider Ownership

CompanyInsider Ownership
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
6.60%
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
7.31%
ObsEva SA stock logo
OBSV
ObsEva
14.40%
Savara Inc. stock logo
SVRA
Savara
5.33%
CompanyEmployeesShares OutstandingFree FloatOptionable
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
604.87 million4.55 millionNot Optionable
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
2010.78 million10.00 millionOptionable
ObsEva SA stock logo
OBSV
ObsEva
5077.97 million66.74 millionNot Optionable
Savara Inc. stock logo
SVRA
Savara
20172.84 million163.63 millionOptionable

Recent News About These Companies

Savara Independent Director Acquires 177% More Stock

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Calithera Biosciences stock logo

Calithera Biosciences NASDAQ:CALA

$0.0001 0.00 (0.00%)
As of 07/8/2025 03:13 PM Eastern

Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

Lantern Pharma stock logo

Lantern Pharma NASDAQ:LTRN

$3.39 -0.15 (-4.24%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$3.38 -0.02 (-0.44%)
As of 05:20 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

ObsEva stock logo

ObsEva NASDAQ:OBSV

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

Savara stock logo

Savara NASDAQ:SVRA

$2.37 +0.10 (+4.41%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$2.40 +0.03 (+1.27%)
As of 04:28 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.